

## Effects of exercise in renal transplant recipients

Giulio Romano, Eric Lorenzon, Domenico Montanaro

Giulio Romano, Eric Lorenzon, Domenico Montanaro, Department of Nephrology, S.M. Misericordia University Hospital, DISM, Piazzale Santa Maria della Misericordia 15, 33100 Udine, Italy

**Author contributions:** Romano G has planned and written the paper; Lorenzon E has contributed both, to the collection and to the analysis of the papers cited in bibliography; Montanaro D has been the supervisor of the final version of the text.

**Correspondence to:** Giulio Romano, MD, Professor of Nephrology, Department of Nephrology, S.M. Misericordia University Hospital, DISM, Piazzale Santa Maria della Misericordia 15, 33100 Udine, Italy. [giulio.romano@uniud.it](mailto:giulio.romano@uniud.it)

Telephone: +39-432-552691 Fax: +39-432-552689

Received: September 2, 2011 Revised: April 2, 2012

Accepted: June 30, 2012

Published online: August 24, 2012

**Key words:** Renal transplantation; Exercise; Working capacity; Quality of life; Cardiovascular risk; Renal function; Immunology

**Peer reviewer:** Yan Chen, PhD, Honorary Assistant Professor, Department of Surgery, The University of Hong Kong, L9-56, Faculty of Medicine Building, 21, Sassoon Road, Pokfulam, Hong Kong, China

Romano G, Lorenzon E, Montanaro D. Effects of exercise in renal transplant recipients. *World J Transplant* 2012; 2(4): 46-50 Available from: URL: <http://www.wjgnet.com/2220-3230/full/v2/i4/46.htm> DOI: <http://dx.doi.org/10.5500/wjt.v2.i4.46>

### Abstract

Even after a successful renal transplantation, the renal transplant recipients (RTRs) keeps on suffering the consequences of the uremic sickness. Cardiovascular risk, work capacity, and quality of life do not improve according to expectations since biological and psychological problems are not completely solved by pharmacological treatment. Furthermore, post-transplant treatment, per se, induces additional problems (i.e., side effects of drugs). It becomes, indeed, very important to insert "non-pharmacological" therapies able to reverse this trend. Exercise may represent an important contribution in the solution of this problem. In fact, many studies have demonstrated, in the last two decades, that physical training is able both, to improve graft function, work capacity and quality of life, and to reduce cardiovascular risk. In conclusion, if the analysis of the available data suggests that an appropriate dose of physical training represent a useful, safe and non-pharmacologic contribution to RTR treatment, it becomes a kidney transplantologist responsibility to introduce exercise in the current therapy of RTRs.

© 2012 Baishideng. All rights reserved.

### BACKGROUND

Uremic patients' survival is conditioned by an increased cardiovascular risk. In spite of the decline of its incidence rate in the general population during the last three decades, cardiovascular events remain the major cause of death in nephropathic patients<sup>[1,2]</sup> with a mortality 10 to 20 higher than in the general population<sup>[3,4]</sup>. In 1998 the National Kidney Foundation Task Force in Cardiovascular Disease recommended to consider uremic patients as a group with very high risk for cardiovascular events<sup>[1]</sup>. The main cause of this raised risk is the accelerated atherosclerosis, which is now considered to be the expression of an inflammatory process<sup>[5,6]</sup>: pro-inflammatory cytokines are secreted by immune cells within the atherosclerotic plaque. These include interleukin (IL)-1, IL-2, IL-6, IL-8, IL-12, IL-10, tumor-necrosis factor, interferon- $\gamma$  and platelet-derived growth factor<sup>[7]</sup>. The accelerated atherosclerosis is the most important late complication for all organ recipients too<sup>[8,9]</sup>. Over the years, various risk factors have been associated with the manifestation of atherosclerosis. Among these, elevated levels of plasma cholesterol (LDL in particular) are recognized as a major risk factor as well as hypertension, diabetes mellitus, smoking<sup>[10]</sup> and sedentary life style<sup>[11]</sup>. An increasing amount of data demonstrates that uremia,

*per se*, represents an inflammatory condition and that this inflammation remains unaffected by transplantation<sup>[12]</sup>. Also in nephropathic patients cardiovascular events are strictly related to inflammation<sup>[13,14]</sup> and they represent the main cause of death not only in predialysis<sup>[15]</sup> and in replacement therapy patients<sup>[16,17]</sup>, but also in renal transplant recipients (RTRs)<sup>[12]</sup>. The immunosuppressive treatment itself contributes to increase cardiovascular complications in RTRs through the induction of hypertension and dyslipidemia<sup>[18,19]</sup>. Moreover, it is important to consider that the tendency to sedentary lifestyle is favoured by both the depression and the reduced quality of life that affect not only dialysed patients<sup>[20,21]</sup> but also patients after a successful renal transplantation<sup>[22]</sup>.

## GOAL

On the basis of the above considerations, the question that arises is the following: Is it possible to reduce cardiovascular risk and to influence graft survival of RTRs other than pharmacologically? In our opinion physical activity could play an important role in this subset of patients. In fact, many studies have demonstrated that physical training is able to improve several factors involved in the increased cardiovascular risk of RTRs and may contribute to save renal function. In this review we will examine the existing evidences with respect to these topics.

## EVIDENCE BASED RESULTS

### Glomerular filtration rate

Greater physical activity is a statistically significant predictor of improved graft function over a 1-year period. The authors believe that physical activity leads to improved cardiovascular function, which, probably, improves perfusion and oxygen delivery to the kidney graft<sup>[23]</sup>.

### Arterial pressure

Exercise reduces the need for pharmacological therapy of hypertension both in lung<sup>[24]</sup> and kidney transplanted patients<sup>[22]</sup>.

### Homocysteine

It is a factor related to an higher prevalence of cardiovascular disease and poorer outcome<sup>[25-29]</sup>. It remains higher in RTRs with respect to general population but an exercise program may significantly decrease the levels of this aminoacid<sup>[30]</sup>.

### Work capacity

Patients with advanced chronic kidney disease have lower cardiorespiratory fitness (CF)<sup>[31,32]</sup> that remains reduced by 30% after transplantation in comparison with age and gender matched control subjects<sup>[33]</sup>. CF expresses the maximum capacity of aerobic activity. It is measured through the evaluation of the peak oxygen uptake (VO<sub>2</sub>) obtained by expired gas analysis. It is important to note that CF is a well-validated predictor of cardiovascular

outcome both in individuals with underlying cardiovascular disease and in normal individuals<sup>[34]</sup>. Exercise improves CF in RTRs<sup>[22,35-37]</sup>. The mechanisms behind this reduced work capacity are not known, but it could be simply due to the reduced activity level before transplantation<sup>[38]</sup>. Exercise enhances muscle strength too<sup>[37,39]</sup>, while it does not modify the body composition (BC), evaluated through dual-energy X-ray absorptiometry<sup>[22,37]</sup>. The lack of difference in the BC is due to the fact that exercise alone is ineffective for weight loss, unless a careful dietary management is adopted<sup>[40]</sup>.

### Effects of exercise among elderly RTRs

Despite best practices, older patients are at increased risk for early graft loss and death<sup>[41]</sup>. It has been demonstrated that pre-transplant inactivity is a negative predictor of overall patients and graft survival in this subset of patients<sup>[42]</sup>.

### Exercise and immunology of kidney transplantation

An 8-wk aerobic exercise program enhances T-helper cell count, CD4+ to CD8+ ratio, natural killer cells activity and IgG and IgM levels without causing graft dysfunction in the short term<sup>[35]</sup>.

Moreover, it has been widely demonstrated that IL-6 plays a significant role in the progression of mesangial proliferative glomerulonephritis<sup>[43]</sup> and that it is an important risk factor with respect to the relapse of IgA nephropathy in transplanted kidney<sup>[44]</sup>. Furthermore, IL-6 amplifies the inflammatory cascade also by promoting the development of Th17 and the synthesis of IL17 from naive T cells (along with TGFβ1 and IL21), whereas the maturation of memory Th17<sup>[45]</sup> and IL17 induces the synthesis of IL6 by myoblasts thus creating a vicious cycle<sup>[46]</sup>. San Segundo *et al.*<sup>[47]</sup> and Afzali *et al.*<sup>[48]</sup> demonstrated that IL-17 serum levels were augmented in graft dysfunction (compared with end stage renal disease patients) and, in agreement with Afzali *et al.*<sup>[48]</sup>, hypothesized that an imbalance between T(H)17 and Tregs enhances immune inflammation among renal transplant patients. In addition, since elevated levels of IL-6 represent a trigger factor of inflammation, they may significantly contribute to the cardiovascular risk of RTRs. Increased basal levels of this cytokine have been measured in RTRs<sup>[49]</sup>.

Castaneda *et al.*<sup>[50]</sup> demonstrated that exercise reduces the levels of IL-6 in uremic patients and we recently showed that this happens in RTRs too<sup>[22]</sup>.

It is interesting to note that IL-6 increase is actually indicated both as the effect of an overtraining syndrome<sup>[51]</sup> and as one of the main factors able to induce an “underperformance syndrome”<sup>[52]</sup>. In fact, during strenuous exercise, IL-6 increases<sup>[53]</sup> by greater amounts than any other cytokine<sup>[54-56]</sup>: an increment registered in behavioral changes during physical as well as psychological stress<sup>[57]</sup>. In agreement with Castaneda *et al.*<sup>[50]</sup> our data<sup>[22]</sup> seem to demonstrate that there is a difference in the IL-6 production depending on the dose of physical training. This can lead to the conclusion that, if strenuous

ous exercise increases IL-6 production, a well regulated level of exercise will produce the opposite result (i.e., a reduction of IL-6 levels). The “appropriate level” of exercise, indicated in several studies regarding the effects of exercise in RTRs, consists of a 30-45 min/session of aerobic exercise (walking or cycling) three or more times per week<sup>[22,23,30,35,37,42,58]</sup>. Therefore data suggest that while the strong exercise is detrimental, the moderate exercise (appropriate level) is of great benefit because it improves, as shown by our experimental *in vivo* in RTR study<sup>[22]</sup>, the physical strength while decreasing IL6 levels, thus clearly indicating that the net biological effect is overwhelmingly positive.

### Anxiety and depression

The quality of life and the psychological status are impaired in patients on maintenance dialysis<sup>[20,21]</sup>. The most common psychological and psychosocial problems are depression, anxiety and social withdrawal<sup>[59-61]</sup>. Anxiety and depression are common in RTRs too<sup>[62]</sup> and contribute to increase cardiovascular risk<sup>[63,64]</sup>.

We have recently demonstrated that physical activity is able to reduce anxiety and depression in RTRs<sup>[22]</sup>.

### Why kidney transplanted patients show low rates of exercise ?

Zhong *et al.*<sup>[65]</sup> got to the bottom of this question: these authors believe it depends on the fear of injuring the transplanted graft<sup>[66,67]</sup>, and/or on the transplant professionals’ silence about the benefits of exercise<sup>[66]</sup>. The cause can sometimes be the protective attitude of the family members and friends<sup>[35]</sup>. Moreover, patients of diverse ethnic and cultural backgrounds may place differential values on exercise and self-care<sup>[68,69]</sup> or this lack of importance given to physical training can be the consequence of the absence of structural support<sup>[65]</sup>.

## CONCLUSION

For patients affected by end-stage renal disease, renal transplant represents a dramatic improvement of quality of life: the freedom from the dialytic treatment might be considered the starting of a second life. Nevertheless, also following a successful renal transplant, several previously taken drugs (i.e., antihypertensive drugs, allopurinol, statins), can’t be stopped, whereas new treatments (i.e., immunosuppressive drugs), have to be started thus increasing per se the cardiovascular risk of RTRs (through drug-induced hypertension and dyslipidemia). This massive drug administration and the need for a strict medical follow-up may justify both the persistence of depression and the interest in “non-pharmacological” therapies, which can improve psychical and physical health of RTRs.

The analysis of the available data allows to state that an appropriate dose of physical training is a useful, safe and non-pharmacological contribution to RTRs treatment through the reduction of the of the risks of car-

diovascular disease, the improvement of the biology of transplantation, the increase of energetic metabolism, and allows for a better quality of life in these subtype of patients. The studies analysed in this review do not distinguish among different subgroups, such as different “age groups”, of RTRs with respect to different physical exercise programs<sup>[22,23,30,35,37,42,58]</sup>. This non-distinction is a further confirmation that, regardless of the type, physical activity can always yield remarkable health benefits. Despite the positive effects of physical activity, most RTRs do not exercise adequately according to the routine practice recommended by the Surgeon General (3 times per week)<sup>[70]</sup>.

It is now the moment to fill this gap, it is now the moment that kidney transplantologists consider exercise not as a luxury accessory, but as integral part in the complex treatment of RTRs

## REFERENCES

- 1 **Levey AS**, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *Am J Kidney Dis* 1998; **32**: 853-906
- 2 **Sarnak MJ**, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raji L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Hypertension* 2003; **42**: 1050-1065
- 3 **Foley RN**, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998; **32**: S112-S119
- 4 **Go AS**, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; **351**: 1296-1305
- 5 **Hansson GK**. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; **352**: 1685-1695
- 6 **García de Tena J**. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; **353**: 429-430; author reply 429-430
- 7 **Kofler S**, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. *Clin Sci (Lond)* 2005; **108**: 205-213
- 8 **Pavarino-Bertelli EC**, Sanches de Alvarenga MP, Goloni-Bertollo EM, Baptista MA, Haddad R, Hoerh NF, Eberlin MN, Abbud-Filho M. Hyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated with chronic allograft nephropathy in renal transplant recipients. *Transplant Proc* 2004; **36**: 2979-2981
- 9 **Covic A**, Mardare N, Gusbeth-Tatomir P, Buhaescu I, Goldsmith DJ. Acute effect of CyA A (Neoral) on large artery hemodynamics in renal transplant patients. *Kidney Int* 2005; **67**: 732-737
- 10 **Assmann G**, Carmena R, Cullen P, Fruchart JC, Jossa F, Lewis B, Mancini M, Paoletti R. Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease. *Circulation* 1999; **100**: 1930-1938



- 11 **Baudet M**, Daugareil C, Ferrieres J. [Cardiovascular disease prevention and life hygiene modifications]. *Ann Cardiol Angeiol* (Paris) 2012; **61**: 93-98
- 12 **Guarnieri G**, Biolo G, Zanetti M, Barazzoni R. Chronic systemic inflammation in uremia: potential therapeutic approaches. *Semin Nephrol* 2004; **24**: 441-445
- 13 **Murtagh BM**, Anderson HV. Inflammation and atherosclerosis in acute coronary syndromes. *J Invasive Cardiol* 2004; **16**: 377-384
- 14 **Danesh J**, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004; **350**: 1387-1397
- 15 **Jungers P**, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. *Nephrol Dial Transplant* 1997; **12**: 2597-2602
- 16 **Baigent C**, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. *Lancet* 2000; **356**: 147-152
- 17 **Harnett JD**, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. *J Am Soc Nephrol* 1994; **4**: 1486-1490
- 18 **Munoz SJ**, Deems RO, Moritz MJ, Martin P, Jarrell BE, Madrey WC. Hyperlipidemia and obesity after orthotopic liver transplantation. *Transplant Proc* 1991; **23**: 1480-1483
- 19 **Kasiske BL**. Risk factors for accelerated atherosclerosis in renal transplant recipients. *Am J Med* 1988; **84**: 985-992
- 20 **Maher BA**, Lamping DL, Dickinson CA, Murawski BJ, Olivier DC, Santiago GC. Psychosocial aspects of chronic hemodialysis: the National Cooperative Dialysis Study. *Kidney Int Suppl* 1983; **S50**-S57
- 21 **Evans RW**, Manninen DL, Garrison LP, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG. The quality of life of patients with end-stage renal disease. *N Engl J Med* 1985; **312**: 553-559
- 22 **Romano G**, Simonella R, Falletti E, Bortolotti N, Deiuri E, Antonutto G, De Vita S, Ferraccioli GF, Montanaro D. Physical training effects in renal transplant recipients. *Clin Transplant* 2010; **24**: 510-514
- 23 **Gordon EJ**, Prohaska TR, Gallant MP, Sehgal AR, Strogatz D, Yucel R, Conti D, Siminoff LA. Longitudinal analysis of physical activity, fluid intake, and graft function among kidney transplant recipients. *Transpl Int* 2009; **22**: 990-998
- 24 **Ross DJ**, Waters PF, Mohsenifar Z, Belman MJ, Kass RM, Koerner SK. Hemodynamic responses to exercise after lung transplantation. *Chest* 1993; **103**: 46-53
- 25 **Veeranna V**, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC, Jacob S, Afonso L. Homocysteine and reclassification of cardiovascular disease risk. *J Am Coll Cardiol* 2011; **58**: 1025-1033
- 26 **Aso Y**, Okumura K, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. *Diabetes Care* 2003; **26**: 2622-2627
- 27 **Teplan V**, Schück O, Stollová M, Vítko S. Obesity and hyperhomocysteinemia after kidney transplantation. *Nephrol Dial Transplant* 2003; **18** Suppl 5: v71-v73
- 28 **Busch M**, Franke S, Müller A, Wolf M, Gerth J, Ott U, Niwa T, Stein G. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. *Kidney Int* 2004; **66**: 338-347
- 29 **Frishman WH**. Biologic markers as predictors of cardiovascular disease. *Am J Med* 1998; **104**: 18S-27S
- 30 **Juskowa J**, Lewandowska M, Bartłomiejczyk I, Foronczewicz B, Korabiewska I, Niewczas M, Sierdziński J. Physical rehabilitation and risk of atherosclerosis after successful kidney transplantation. *Transplant Proc* 2006; **38**: 157-160
- 31 **Clyne N**. Physical working capacity in uremic patients. *Scand J Urol Nephrol* 1996; **30**: 247-252
- 32 **Painter P**, Messer-Rehak D, Hanson P, Zimmerman SW, Glass NR. Exercise capacity in hemodialysis, CAPD, and renal transplant patients. *Nephron* 1986; **42**: 47-51
- 33 **Kjaer M**, Keiding S, Engfred K, Rasmussen K, Sonne B, Kirkegård P, Galbo H. Glucose homeostasis during exercise in humans with a liver or kidney transplant. *Am J Physiol* 1995; **268**: E636-E644
- 34 **Myers J**, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. *N Engl J Med* 2002; **346**: 793-801
- 35 **Surgit O**, Ersoz G, Gursel Y, Ersoz S. Effects of exercise training on specific immune parameters in transplant recipients. *Transplant Proc* 2001; **33**: 3298
- 36 **Armstrong K**, Rakhit D, Jeffriess L, Johnson D, Leano R, Prins J, Garske L, Marwick T, Isbel N. Cardiorespiratory fitness is related to physical inactivity, metabolic risk factors, and atherosclerotic burden in glucose-intolerant renal transplant recipients. *Clin J Am Soc Nephrol* 2006; **1**: 1275-1283
- 37 **Painter PL**, Hector L, Ray K, Lynes L, Dibble S, Paul SM, Tomlanovich SL, Ascher NL. A randomized trial of exercise training after renal transplantation. *Transplantation* 2002; **74**: 42-48
- 38 **Kjaer M**, Beyer N, Secher NH. Exercise and organ transplantation. *Scand J Med Sci Sports* 1999; **9**: 1-14
- 39 **Kempeneers G**, Noakes TD, van Zyl-Smit R, Myburgh KH, Lambert M, Adams B, Wiggins T. Skeletal muscle limits the exercise tolerance of renal transplant recipients: effects of a graded exercise training program. *Am J Kidney Dis* 1990; **16**: 57-65
- 40 **Franz MJ**, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD, Pronk NP. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. *J Am Diet Assoc* 2007; **107**: 1755-1767
- 41 **Ismail N**, Hakim RM, Helderman JH. Renal replacement therapies in the elderly: Part II. Renal transplantation. *Am J Kidney Dis* 1994; **23**: 1-15
- 42 **Yango AF**, Gohh RY, Monaco AP, Reinert SE, Gautam A, Dworkin LD, Morrissey PE. Excess risk of renal allograft loss and early mortality among elderly recipients is associated with poor exercise capacity. *Clin Nephrol* 2006; **65**: 401-407
- 43 **Horii Y**, Iwano M, Hirata E, Shiiki M, Fujii Y, Dohi K, Ishikawa H. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. *Kidney Int Suppl* 1993; **39**: S71-S75
- 44 **Odum J**, Peh CA, Clarkson AR, Bannister KM, Seymour AE, Gillis D, Thomas AC, Mathew TH, Woodroffe AJ. Recurrent mesangial IgA nephritis following renal transplantation. *Nephrol Dial Transplant* 1994; **9**: 309-312
- 45 **Miossec P**, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. *N Engl J Med* 2009; **361**: 888-898
- 46 **Chevrel G**, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. *J Neuroimmunol* 2003; **137**: 125-133
- 47 **San Segundo D**, López-Hoyos M, Fernández-Fresnedo G, Benito MJ, Ruiz JC, Benito A, Rodrigo E, Arias M. T(H)17 versus Treg cells in renal transplant candidates: effect of a previous transplant. *Transplant Proc* 2008; **40**: 2885-2888
- 48 **Afzali B**, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. *Clin Exp Immunol* 2007; **148**: 32-46
- 49 **Cueto-Manzano AM**, Morales-Buenrostro LE, González-Espinoza L, González-Tableros N, Martín-del-Campo F, Correa-Rotter R, Valera I, Alberú J. Markers of inflammation before and after renal transplantation. *Transplantation* 2005;

- 80: 47-51
- 50 **Castaneda C**, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. *Am J Kidney Dis* 2004; **43**: 607-616
- 51 **Budgett R**, Newsholme E, Lehmann M, Sharp C, Jones D, Peto T, Collins D, Nerurkar R, White P. Redefining the over-training syndrome as the unexplained underperformance syndrome. *Br J Sports Med* 2000; **34**: 67-68
- 52 **Robson P**. Elucidating the unexplained underperformance syndrome in endurance athletes : the interleukin-6 hypothesis. *Sports Med* 2003; **33**: 771-781
- 53 **Pedersen BK**, Steensberg A, Fischer C, Keller C, Ostrowski K, Schjerling P. Exercise and cytokines with particular focus on muscle-derived IL-6. *Exerc Immunol Rev* 2001; **7**: 18-31
- 54 **Nieman DC**, Nehlsen-Cannarella SL, Fagoaga OR, Henson DA, Utter A, Davis JM, Williams F, Butterworth DE. Influence of mode and carbohydrate on the cytokine response to heavy exertion. *Med Sci Sports Exerc* 1998; **30**: 671-678
- 55 **Ostrowski K**, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. *J Physiol* 1999; **515** (Pt 1): 287-291
- 56 **Ullum H**, Haahr PM, Diamant M, Palmø J, Halkjaer-Kristensen J, Pedersen BK. Bicycle exercise enhances plasma IL-6 but does not change IL-1 alpha, IL-1 beta, IL-6, or TNF-alpha pre-mRNA in BMNC. *J Appl Physiol* 1994; **77**: 93-97
- 57 **Baker DG**, Ekhtor NN, Kasckow JW, Hill KK, Zoumakis E, Dashevsky BA, Chrousos GP, Geraciotti TD. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. *Neuroimmunomodulation* 2001; **9**: 209-217
- 58 **Painter PL**, Hector L, Ray K, Lynes L, Paul SM, Dodd M, Tomlanovich SL, Ascher NL. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. *Am J Kidney Dis* 2003; **42**: 362-369
- 59 **McKee DC**, Burnett GB, Raft DD, Batten PG, Bain KP. Longitudinal study of neuropsychological functioning in patients on chronic hemodialysis: a preliminary report. *J Psychosom Res* 1982; **26**: 511-518
- 60 **Chen CK**, Tsai YC, Hsu HJ, Wu IW, Sun CY, Chou CC, Lee CC, Tsai CR, Wu MS, Wang LJ. Depression and suicide risk in hemodialysis patients with chronic renal failure. *Psychosomatics* 2010; **51**: 528-528.e6
- 61 **Levenson JL**, Glocheski S. Psychological factors affecting end-stage renal disease. A review. *Psychosomatics* 1991; **32**: 382-389
- 62 **Arapaslan B**, Soykan A, Soykan C, Kumbasar H. Cross-sectional assessment of psychiatric disorders in renal transplantation patients in Turkey: a preliminary study. *Transplant Proc* 2004; **36**: 1419-1421
- 63 **Sardinha A**, Araújo CG, Soares-Filho GL, Nardi AE. Anxiety, panic disorder and coronary artery disease: issues concerning physical exercise and cognitive behavioral therapy. *Expert Rev Cardiovasc Ther* 2011; **9**: 165-175
- 64 **Celano CM**, Huffman JC. Depression and cardiac disease: a review. *Cardiol Rev* 2011; **19**: 130-142
- 65 **Zhong R**, Burk DH, Nairn CJ, Wood-Jones A, Morrison WH, Ye ZH. Mutation of SAC1, an Arabidopsis SAC domain phosphoinositide phosphatase, causes alterations in cell morphogenesis, cell wall synthesis, and actin organization. *Plant Cell* 2005; **17**: 1449-1466
- 66 **Painter P**. Exercise after renal transplantation. *Adv Ren Replace Ther* 1999; **6**: 159-164
- 67 **Luk WS**. The HRQoL of renal transplant patients. *J Clin Nurs* 2004; **13**: 201-209
- 68 **Tudor-Locke C**, Henderson KA, Wilcox S, Cooper RS, Durstine JL, Ainsworth BE. In their own voices: definitions and interpretations of physical activity. *Womens Health Issues* 2003; **13**: 194-199
- 69 **Becker G**, Beyene Y, Newsom EM, Rodgers DV. Knowledge and care of chronic illness in three ethnic minority groups. *Fam Med* 1998; **30**: 173-178
- 70 **Nelson ME**, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera CA, Castaneda-Sceppa C. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc* 2007; **39**: 1435-1445

S- Editor Cheng JX L- Editor A E- Editor Zheng XM